contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-oyj-aiforia-technologies-plcs-financial-reporting-and-annual-general-meeting-in-financial-year-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

When one really doesn’t want to trust only the company’s own announcements… Inderes, of course, also hypes it up, but but.. a feather in their cap, of course, if it breaks through. Or their reputation goes, if they still have any  Also here, just among other players                   Lumea – 18 Sep 24              Top 10 AI Companies for Digital Pathology | Lumea    Artificial Intelligence is advancing digital pathology and improving patient care. Here are the top AI companies that are leading the charge.         Est. reading time: 7 minutes

This case study published on Aiforia’s website at the end of November was interesting. In this study, a deep learning model created and trained with Aiforia Create successfully predicted the effectiveness of chemotherapy better than previously possible based on traditional clinical data. As I understand it, competitors haven’t really offered such deep learning AI.            aiforia.com              Case study: predicting the outcome of neoadjuvant chemotherapy for breast...    Dr. Sturm et al. used Aiforia® Create to develop an AI model to predict the outcome of neoadjuvant chemotherapy for breast cancer patients, pre-operation.

Should this be updated, as it was already the same in 01.2024. One could reach a profit with about 20 million in revenue, which is “only” 6 times the current one. In God’s hands

As I recall, the CEO expects 27 items to turn positive regarding operating profit.

So, the operating profit would be positive in 2030. However, a few years ago Inderes predicted this year’s revenue to be 16 million, but it will be about 3.3 million ..So, the CEO is at least good at talking

I’m almost a complete novice when it comes to Aiforia, but at a quick glance, the company raised a decent sum during its IPO, which carried it a good way forward. After those funds evaporated, financing has had to be sought in smaller tranches, and the share price development hasn’t been helpful either:  With the IPO price being 5.01 euros, many investors have been bitterly disappointed here too. At what point does Inderes expect the cash flow to turn positive, in other words, how long will this still be on life support?

That is also possible, but it’s difficult for an outsider like me to say for sure how things stand (and with which companies). My experience is that in companies at this development stage, management’s view of their company’s value is almost without exception higher than the share price. This also applies to the majority of listed companies and is probably at least partly due to the fact that they believe more in their own work than the market does. But this would suggest that the motive for smaller raises could just as well be management’s confidence in potentially better terms available in a later round, rather than limitations in funding availability.

Aiforia Technologies

Aiforia Technologies Plc, Company release, December 4, 2023 at 09:00 a.m. EETThe calendar for Aiforia Technologies Plc's financial reporting concerning the financial year 2024 is as follows:...

<div class="abstract">Aiforia Technologies Plc, Company release, December 4, 2023 at 09:00 a.m. EET</div>The calendar for Aiforia Technologies Plc's financial reporting concerning the financial year 2024 is as follows: &nbsp;<ul><li>March 7, 2024: Financial Statements Bulletin for financial year 2023</li><li></li></ul>March 13, 2024: The Financial Statements and the Board of Directors' Report for financial year 2023<ul><li></li></ul>August 29, 2024: Half-Year Financial Report for 1 January-30 June 2024Aiforia Technologies's Annual General Meeting will be held on April 4, 2024. The Board of Directors will convene the meeting with a separate company release at a later date.&nbsp; &nbsp;More information on the events of the financial year will be available on the company's investor pages at <a href="https://investors.aiforia.com/investor-calendar">https://investors.aiforia.com/investor-calendar</a>.Further inquiriesVeli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878 <a href="https://investors.aiforia.com/%C2%A0">https://investors.aiforia.com/&nbsp;</a> &nbsp;(<a href="https://investors.aiforia.com/%C2%A0">https://investors.aiforia.com/&nbsp;</a>)Certified AdviserUB Securities Ltdubs@unitedbankers.fiAbout AiforiaAiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.Find out more atwww.aiforia.com